Figure 4.
The combination of anti-PD-1/PD-L1 therapy with other therapies has become an important treatment strategy. The strategies used in combination with anti-PD-1/PD-L1 therapy include radiotherapy, chemotherapy, oncolytic viral therapy, anti-angiogenic therapy, CAR-T therapy, and CD73 inhibition therapy. PD-1, programmed death 1; PD-L1, programmed death 1 ligand; CAR-T therapy, chimeric antigen receptor T therapy.